跳至主要内容
临床试验/EUCTR2021-002185-40-IS
EUCTR2021-002185-40-IS招募中1 期

Comparison of the Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion and Plasma Levels in Patients with Adenine Phosphoribosyltransferase Deficiency: A Clinical Trial

andspitali - The National University Hospital of Iceland0 个研究点目标入组 10 人开始时间: 2024年7月8日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Subjects =18 years of age with confirmed (genetic testing or APRT enzyme activity measurements) adenine phosphoribosyltransferase (APRT) deficiency who are participating in the APRT Deficiency Registry of the Rare Kidney Stone Consortium are eligible for the study.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 8
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 2

排除标准

  • 1. Patients do not want to interrupt drug treatment as requested in trial protocol.
  • 2. No other exclusion criteria if inclusion criteria are met.

研究者

发起方
andspitali - The National University Hospital of Iceland

相似试验

Allopurinol and Febuxostat Treatment in Patients... | 临床试验